CVS Caremark Corp. (NYSE:CVS) reports preliminary financial results for the quarter ended 2012-09-30.
CVS Caremark Corp. recently reported its preliminary financial results based on which CapitalCube provides a unique peer-based analysis of the company. Our analysis is based on the company's performance over the last twelve months (unless stated otherwise).
CVS Caremark Corp.'s analysis versus peers uses the following peer-set: Walgreen Co. (WAG), Shoppers Drug Mart Corp. (NYSE:SC), Sundrug Co. Ltd. (9989), Rite Aid Corp. (NYSE:RAD), BioScrip Inc. (NASDAQ:BIOS), PharMerica Corp. (NYSE:PMC) and PetMed Express Inc. (NASDAQ:PETS). The table below shows the preliminary results along with the recent trend for revenues, net income and returns.
|Quarterly (USD million)||2012-09-30||2012-06-30||2012-03-31||2011-12-31||2011-09-30|
|Revenue Growth %||(1.6)||(0.3)||8.8||6.2||0.2|
|Net Income Growth %||4.6||24.5||(29.4)||26.7||6.2|
|Net Margin %||3.3||3.1||2.5||3.9||3.3|
|ROE % (Annualized)||10.8||10.2||8.2||11.6||9.2|
|ROA % (Annualized)||6.2||5.9||4.8||6.8||5.3|
CVS Caremark Corp.'s current Price/Book of 1.6 is about median in its peer group. The market expects CVS Caremark Corp. to grow at about the same rate as its chosen peers (PE of 15.4 compared to peer median of 14.5) and to maintain the peer median return (ROE of 10.4%) it currently generates.
The company employs relatively high amounts of assets (with a turnover of 1.8x compared to peer median of 2.4x) while generating profit margins of 3.2% that are only about median among its chosen peers. CVS Caremark Corp.'s net margin is its lowest relative to the last five years and compares to a high of 3.8% in 2008.Economic Moat
The company has achieved better revenues growth than its chosen peers (year-on-year change in revenues of 11.1%) but its earnings growth performance has been below the median (change in annual reported earnings of 1.5% compared to the peer median of 18.8%). This suggests that, compared to its peers, the company is focused more on top-line revenues. CVS Caremark Corp. is currently converting every 1% of change in revenue into 0.1% change in annual reported earnings.
CVS Caremark Corp.'s return on assets currently is around peer median (5.9% vs. peer median 6.5%) -- similar to its returns over the past five years (6.0% vs. peer median 7.4%). This performance suggests that the company has no specific competitive advantages relative to its peers.
The company's comparatively low gross margins of 19.2% versus peer median of 26.4% suggests that it has a non-differentiated strategy or is in a pricing constrained position. However, CVS Caremark Corp.'s pre-tax margin of 5.3% is around the peer median which, when combined with the gross margin, suggests lower operating costs relative to peers.Growth & Investment Strategy
While CVS Caremark Corp.'s revenues have grown faster than the peer median (7.0% vs. 3.9% respectively for the past three years), the market gives the stock an about peer median PE ratio of 15.4. This suggests that the market has some questions about the company's long-term strategy.
CVS Caremark Corp.'s annualized rate of change in capital of 1.2% over the past three years is less than its peer median of 4.8%. This investment has generated a peer median return on capital of 7.5% averaged over the same three years. The median return on capital investment on a relatively lower investment suggests that the company is under investing.Earnings Quality
CVS Caremark Corp.'s reported net income margin for the last twelve months is around the peer median (3.2% vs. peer median of 3.1%). However, the company has also recorded a relatively low level of accruals (1.6% vs. peer median of 2.1%) which suggests possible overstatement of its reported net income.
CVS Caremark Corp.'s accruals over the last twelve months are around zero. However, this modestly positive level is also less than the peer median which suggests some amount of building of reserves.Trend Charts
CVS Caremark Corp. is a pharmacy health care provider in the U.S. with integrated offerings across the entire spectrum of pharmacy care. The company operates in the following segments: Pharmacy Services, Retail Pharmacy and Corporate. CVS Caremark was founded in 1963 and is headquartered in Woonsocket, RI.
The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party's use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you're agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website analytixinsight.com.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.